Dyskinesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Dec. 22, 2011 - PRLog -- The global market for dyskinesia therapeutics was valued at approximately $302.3m in 2011 and is expected to reach $480m by 2019 at a Compound Annual Growth Rate (CAGR) of 6%. The dyskinesia therapeutics market is derived from the patient pool of Levodopa-Induced Dyskinesia (LID) and Tardive
Dyskinesia (TD). LID is caused by levodopa, a widely used treatment option for Parkinson’s disease (PD).
The continuing usage of levodopa in PD has resulted in an increase in the prevalence of LID. At present
amantadine is used for LID as an adjuvant treatment to levodopa. TD is caused by long-term use of the antipsychotics currently prescribed for various psychiatric disorders such as schizophrenia, bipolar disorder, depression and others. The antipsychotics prescription pattern has witnessed a shift from the
typical antipsychotics (such as haloperidol) to atypical antipsychotics (such as olanzapine, aripiprazole, quetiapine, risperidone and others). This shift has resulted in a reduction in the risk of TD. According to
the National Institute of Neurological Disorders and Stroke (NINDS), tetrabenazine is the preferred offlabel treatment option for TD, despite not being currently approved for dyskinesia by regulatory bodies such as the Food and Drug Administration (FDA) in the US, the European Medical Agency (EMEA), or others. The unfavorable side effect profile of tetrabenazine has restricted its use. In the US, tetrabenazine is available under the brand name Xenazine and is approved for Huntington’s disease. Tetrabenazine is generic in the European and Japanese markets. According to current estimates, the US market accounts for 44% of the global dyskinesia therapeutics market

The late stage dyskinesia pipeline has only one molecule, ADS-5102 (Adamas Pharmaceuticals), currently in Phase II/III. This is a product extension of amantadine and is not expected to have a significant impact on the market. It is estimated that ADS-5102 might enter the dyskinesia therapeutics market by 2016. The lack of promising drugs in the pipeline and the patent expiry of Xenazine in the US market will result in only moderate growth of the dyskinesia therapeutics through the forecast period 2019.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx...

The dyskinesia therapeutics market has significant unmet need because of the absence of approved products to treat the disorder. The commonly used treatment options for dyskinesia include tetrabenazine and amantadine, which are focused on reducing the severity of dyskinesia induced by levodopa and antipsychotics. A limited number of studies indicate the use of other drugs such as reserpine, clozapine, dextromethorphan, idazoxan, riluzole, istradefylline, memantine, nabilone, quetiapine, remacemide, and propranolol for dyskinesia. However, GlobalData’s analysis of the dyskinesia therapeutics market indicates that the future market will continue to have high unmet need due to absence of new diseasemodifying therapies in the pipeline. Research and development will need to be centered upon identifying new ways to treat and prevent dyskinesia.

GlobalData, the industry analysis specialist, has released its new report, “Dyskinesia Therapeutics- Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global dyskinesia market. The report identifies the key trends shaping and driving the global dyskinesia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dyskinesia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Dyskines...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.